|
WO1999029310A2
(en)
|
1997-12-05 |
1999-06-17 |
Medical College Of Georgia Research Institute, Inc. |
Regulation of t cell-mediated immunity by tryptophan and its analogs
|
|
SE0102168D0
(sv)
*
|
2001-06-19 |
2001-06-19 |
Karolinska Innovations Ab |
New use and new compounds
|
|
WO2004094409A1
(en)
*
|
2003-03-27 |
2004-11-04 |
Lankenau Institute For Medical Research |
Novel ido inhibitors and methods of use
|
|
US20050186289A1
(en)
*
|
2003-04-01 |
2005-08-25 |
Medical College Of Georgia Research Institute, Inc. |
Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
|
|
US7598287B2
(en)
|
2003-04-01 |
2009-10-06 |
Medical College Of Georgia Research Institute, Inc. |
Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
|
|
DE10348044A1
(de)
|
2003-10-15 |
2005-05-19 |
Imtm Gmbh |
Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
|
|
CA2581674A1
(en)
|
2004-07-13 |
2006-01-19 |
The University Of British Columbia |
Indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
US7781478B2
(en)
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
|
US20060160883A1
(en)
*
|
2005-01-14 |
2006-07-20 |
Stoops Linda M |
Regulation of immune system action in mammals through use of a multi-tiered model of immune system function
|
|
PL1879573T3
(pl)
|
2005-05-10 |
2013-05-31 |
Incyte Holdings Corp |
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
|
CA2626547A1
(en)
*
|
2005-10-21 |
2007-05-03 |
Medical College Of Georgia Research Institute, Inc. |
The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
|
|
US7705022B2
(en)
|
2005-10-27 |
2010-04-27 |
Lankenau Institute For Medical Research |
IDO inhibitors and methods of use thereof
|
|
WO2007050963A1
(en)
*
|
2005-10-27 |
2007-05-03 |
Lankenau Institute For Medical Research |
Novel ido inhibitors and methods of use thereof
|
|
DE102005053947A1
(de)
*
|
2005-11-11 |
2007-05-16 |
Univ Ernst Moritz Arndt |
Neue Arzneimittel
|
|
CA2634198C
(en)
|
2005-12-20 |
2014-06-03 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
US20090155311A1
(en)
*
|
2006-01-07 |
2009-06-18 |
Med. College Of Georgia Research Institute, Inc. |
Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
|
|
JP2007320859A
(ja)
*
|
2006-05-30 |
2007-12-13 |
Kao Corp |
活性酸素産生酵素発現抑制剤
|
|
WO2008022256A2
(en)
*
|
2006-08-16 |
2008-02-21 |
Blagosklonny Mikhail V |
Methods and compositions for preventing or treating age-related diseases
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
ES2444574T3
(es)
|
2006-09-19 |
2014-02-25 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
|
|
JP2008074744A
(ja)
*
|
2006-09-20 |
2008-04-03 |
Kao Corp |
血圧降下剤
|
|
JP2008074745A
(ja)
*
|
2006-09-20 |
2008-04-03 |
Kao Corp |
血糖上昇抑制剤
|
|
JP2008074742A
(ja)
*
|
2006-09-20 |
2008-04-03 |
Kao Corp |
血糖上昇抑制剤
|
|
WO2009033183A2
(en)
*
|
2007-09-08 |
2009-03-12 |
University Of Florida Research Foundation |
Compounds and methods for treatment of hcv and conditions associated with cd81 binding
|
|
JP5583592B2
(ja)
*
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ｉｄｏ阻害剤
|
|
US20110059137A1
(en)
*
|
2008-03-21 |
2011-03-10 |
H. Lee Moffitt Cancer Center And Research Institutute, Inc |
Chemokine gene-modified cells for cancer immunotherapy
|
|
US20110159017A1
(en)
*
|
2008-04-11 |
2011-06-30 |
Ludwig Institute For Cancer Research Ltd. |
Trytophan catabolism in cancer treatment and diagnosis
|
|
ES2657963T3
(es)
|
2008-04-17 |
2018-03-07 |
Io Biotech Aps |
Inmunoterapia basada en indolamina 2,3-dioxigenasa
|
|
JP2011518841A
(ja)
*
|
2008-04-24 |
2011-06-30 |
ニューリンク ジェネティクス， インコーポレイテッド |
Ｉｄｏ阻害剤
|
|
US11058699B2
(en)
*
|
2008-07-01 |
2021-07-13 |
Wisconsin Alumni Research Foundation |
Method and compositions for inhibition of double stranded DNA viruses
|
|
PL2315756T3
(pl)
|
2008-07-08 |
2015-02-27 |
Incyte Holdings Corp |
1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
|
|
WO2010042685A2
(en)
*
|
2008-10-08 |
2010-04-15 |
Medical College Of Georgia Research Institute, Inc. |
Inhibitors of the atb(0,+) transporter and uses thereof
|
|
CA2772760A1
(en)
|
2008-12-23 |
2010-07-01 |
President And Fellows Of Harvard College |
Small molecule inhibitors of necroptosis
|
|
US20100261774A1
(en)
*
|
2009-02-13 |
2010-10-14 |
Children's Hospital Medical Center |
Methods for the modulation of Leishmania major infection in mammals
|
|
AU2010233073B2
(en)
|
2009-04-10 |
2014-07-31 |
Haiyan Qi |
Novel anti-aging agents and methods to identify them
|
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
|
EP2533779A4
(en)
*
|
2010-02-09 |
2013-08-21 |
Georgia Health Sciences University Res Inst Inc |
ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE
|
|
EP2422848A1
(en)
|
2010-08-18 |
2012-02-29 |
Grindeks, a joint stock company |
Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
|
|
CN102370638B
(zh)
*
|
2010-08-20 |
2013-10-23 |
南京大学 |
3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用
|
|
US8933119B2
(en)
|
2011-01-03 |
2015-01-13 |
The William M. Yarbrough Foundation |
Method for treating phytophotodermatitis
|
|
US10640464B2
(en)
|
2011-01-03 |
2020-05-05 |
The William M. Yarbrough Foundation |
Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
|
|
US9962361B2
(en)
|
2011-01-03 |
2018-05-08 |
The William M. Yarbrough Foundation |
Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
|
|
US10647668B2
(en)
|
2011-01-03 |
2020-05-12 |
The William M. Yarbrough Foundation |
Isothiocyanate functional surfactant and associated method of use
|
|
US10617478B1
(en)
|
2011-01-03 |
2020-04-14 |
Smith & Nephew Orthopedics AG |
Surgical implement selection process
|
|
US11279674B2
(en)
|
2011-01-03 |
2022-03-22 |
The William M. Yarbrough Foundation |
Isothiocyanate functional surfactant and associated method of use
|
|
US10273205B2
(en)
|
2011-01-03 |
2019-04-30 |
The William M. Yarbrough Foundation |
Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
|
|
US11407713B2
(en)
|
2011-01-03 |
2022-08-09 |
The William M. Yarbrough Foundation |
Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
|
|
US10308599B2
(en)
|
2011-01-03 |
2019-06-04 |
The William M. Yarbrough Foundation |
Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
|
|
US8865765B2
(en)
|
2011-01-12 |
2014-10-21 |
The William M. Yarbrough Foundation |
Method for treating eczema
|
|
US9532969B2
(en)
|
2011-02-08 |
2017-01-03 |
The William M. Yarbrough Foundation |
Method for treating psoriasis
|
|
NO2694640T3
(https=)
|
2011-04-15 |
2018-03-17 |
|
|
|
WO2013067142A1
(en)
*
|
2011-11-02 |
2013-05-10 |
Medivation Technologies, Inc. |
Compounds and treatment methods
|
|
US20130129680A1
(en)
*
|
2011-11-23 |
2013-05-23 |
Thomas Christian Lines |
Method for treating hepatitis c virus infection using quercetin-containing compositions
|
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
|
US10441561B2
(en)
|
2012-07-26 |
2019-10-15 |
The William M. Yanbrough Foundation |
Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
|
|
US9839621B2
(en)
|
2012-07-26 |
2017-12-12 |
The William M. Yarbrough Foundation |
Method for treating bladder cancer
|
|
US10434082B2
(en)
|
2012-07-26 |
2019-10-08 |
The William M. Yarbrough Foundation |
Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
|
|
US10335387B2
(en)
|
2012-07-26 |
2019-07-02 |
The William M. Yarbrough Foundation |
Method for treating infectious diseases with isothiocyanate functional compounds
|
|
US9949943B2
(en)
|
2012-07-26 |
2018-04-24 |
The William M. Yarbrough Foundation |
Method for treating neurodegenerative diseases
|
|
US10434081B2
(en)
|
2012-07-26 |
2019-10-08 |
The William M. Yarbrough Foundation |
Inhibitors of macrophage migration inhibitory factor
|
|
US8865772B2
(en)
|
2012-07-26 |
2014-10-21 |
The William M. Yarbrough Foundation |
Method for treating skin cancer
|
|
US10080734B2
(en)
|
2012-07-26 |
2018-09-25 |
The William M. Yarbrough Foundation |
Method for treating autism and other neurodevelopmental disorders
|
|
CA2889182A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
JP2016501203A
(ja)
|
2012-11-20 |
2016-01-18 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
|
|
CN105209449B
(zh)
|
2013-03-14 |
2019-02-01 |
库拉德夫制药私人有限公司 |
犬尿氨酸途径的抑制剂
|
|
SG11201507255QA
(en)
|
2013-03-14 |
2015-10-29 |
Newlink Genetics Corp |
Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
|
|
MY171854A
(en)
|
2013-03-29 |
2019-11-05 |
Sumitomo Dainippon Pharma Co Ltd |
Wt1 antigen peptide conjugate vaccine
|
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
CN105764501A
(zh)
|
2013-07-26 |
2016-07-13 |
现代化制药公司 |
改善比生群治疗效益的组合物
|
|
KR102271498B1
(ko)
*
|
2013-08-30 |
2021-07-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
종양 치료를 위한 키누레닌 고갈 효소의 투여
|
|
US10307406B2
(en)
|
2013-08-31 |
2019-06-04 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor
|
|
DK3066085T3
(da)
|
2013-11-08 |
2020-06-02 |
Incyte Holdings Corp |
Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
|
|
WO2015082499A2
(en)
|
2013-12-03 |
2015-06-11 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
GB201322673D0
(en)
*
|
2013-12-20 |
2014-02-05 |
Tpp Global Dev Ltd |
Screening method
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN106535884A
(zh)
|
2014-06-06 |
2017-03-22 |
弗雷克萨斯生物科学公司 |
免疫调节剂
|
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
JP7080053B2
(ja)
|
2014-08-29 |
2022-06-03 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
|
|
UY36391A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
|
MX2017005462A
(es)
|
2014-11-05 |
2017-07-28 |
Flexus Biosciences Inc |
Agentes inmunorreguladores.
|
|
US10525035B2
(en)
|
2014-12-18 |
2020-01-07 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
WO2016147144A1
(en)
*
|
2015-03-17 |
2016-09-22 |
Pfizer Inc. |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
|
JP6801159B2
(ja)
|
2015-04-21 |
2020-12-16 |
ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． |
イミダゾイソインドール誘導体、その製造方法及びその医薬用途
|
|
JP6515182B2
(ja)
*
|
2015-05-20 |
2019-05-15 |
大日本住友製薬株式会社 |
Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
|
|
IL274572B2
(en)
|
2015-07-16 |
2024-01-01 |
Biolinerx Ltd |
Compositions and methods for treating cancer
|
|
EP3954369B1
(en)
|
2015-07-24 |
2025-08-20 |
Lumos Pharma, Inc. |
Salts and prodrugs of 1-methyl-d-tryptophan
|
|
WO2017045691A1
(en)
|
2015-09-16 |
2017-03-23 |
Herlev Hospital |
Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
|
|
CN108601767A
(zh)
*
|
2015-10-05 |
2018-09-28 |
卡利泰拉生物科技公司 |
用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
|
|
EP3370773B1
(en)
*
|
2015-11-04 |
2022-01-05 |
Duke University |
Combination therapy of immunotoxin and checkpoint inhibitor
|
|
EP3370699A1
(en)
|
2015-11-04 |
2018-09-12 |
Incyte Corporation |
Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
|
|
WO2017080934A1
(en)
*
|
2015-11-09 |
2017-05-18 |
F. Hoffmann-La Roche Ag |
Screening assay to identify id01 and/or tdo modulators
|
|
US10538497B2
(en)
|
2015-12-15 |
2020-01-21 |
Merck Sharp & Dohme Corp. |
Compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
TW201730190A
(zh)
|
2015-12-24 |
2017-09-01 |
Genentech Inc |
Ｔｄｏ２抑制劑
|
|
US11752131B2
(en)
|
2016-02-19 |
2023-09-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
US11066383B2
(en)
|
2016-05-04 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN109414420A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP2019516682A
(ja)
*
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
EP3503891A1
(en)
|
2016-08-26 |
2019-07-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2018039518A1
(en)
|
2016-08-26 |
2018-03-01 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3504185B1
(en)
*
|
2016-08-29 |
2021-11-24 |
Merck Sharp & Dohme Corp. |
Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
EP3515914A4
(en)
|
2016-09-24 |
2020-04-15 |
BeiGene, Ltd. |
INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
|
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
|
EP3549957A4
(en)
|
2016-11-30 |
2020-08-05 |
Sumitomo Dainippon Pharma Co., Ltd. |
AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
CN106905256A
(zh)
*
|
2017-03-06 |
2017-06-30 |
中国药科大学 |
苯并五元杂环类ido1抑制剂、其制备方法及应用
|
|
JP7343902B2
(ja)
*
|
2017-03-14 |
2023-09-13 |
エスジェーティー モレキュラー リサーチ，エスエル |
非アルコール性脂肪性肝疾患と非アルコール性脂肪性肝炎の予防および／または処置に使用するための化合物
|
|
WO2018175954A1
(en)
|
2017-03-23 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
|
|
US11034661B2
(en)
|
2017-03-29 |
2021-06-15 |
Merck Sharp & Dohme Corp. |
Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
|
|
CN108727361A
(zh)
|
2017-04-24 |
2018-11-02 |
南京药捷安康生物科技有限公司 |
吲哚胺2,3-双加氧酶抑制剂与应用
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11433143B2
(en)
|
2017-05-18 |
2022-09-06 |
The Regents Of The University Of California |
Nano-enabled immunotherapy in cancer
|
|
EP3645533B1
(en)
|
2017-06-28 |
2025-03-26 |
Genentech, Inc. |
Tdo2 and ido1 inhibitors
|
|
US11827639B2
(en)
|
2017-06-28 |
2023-11-28 |
Genentech, Inc. |
TDO2 and IDO1 inhibitors
|
|
EP3675877A1
(en)
|
2017-08-31 |
2020-07-08 |
Multimmune GmbH |
Hsp70 based combination therapy
|
|
WO2019055786A1
(en)
|
2017-09-14 |
2019-03-21 |
Lankenau Institute For Medical Research |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2019078246A1
(ja)
|
2017-10-19 |
2019-04-25 |
一般社団法人ファルマバレープロジェクト支援機構 |
Ｉｄｏ／ｔｄｏ阻害剤
|
|
JP6931145B2
(ja)
*
|
2017-11-30 |
2021-09-01 |
株式会社オプトクリエーション |
オゾンナノバブルの抗がん剤
|
|
EP3697423A4
(en)
|
2018-01-05 |
2021-08-11 |
Dicerna Pharmaceuticals, Inc. |
REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP7302793B2
(ja)
|
2018-03-08 |
2023-07-04 |
国立大学法人 東京大学 |
Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法
|
|
US20190314324A1
(en)
|
2018-04-13 |
2019-10-17 |
The University Of Chicago |
Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
|
|
CA3096549A1
(en)
|
2018-04-16 |
2019-10-24 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzymes and uses thereof
|
|
GB201809050D0
(en)
|
2018-06-01 |
2018-07-18 |
E Therapeutics Plc |
Modulators of tryptophan catabolism
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12139551B2
(en)
|
2018-12-03 |
2024-11-12 |
Bristol-Myers Squibb Company |
Anti-IDO antibody and uses thereof
|
|
WO2023225324A1
(en)
*
|
2022-05-20 |
2023-11-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating fatty liver and viral infections
|
|
GB202303250D0
(en)
|
2023-03-06 |
2023-04-19 |
King S College London |
Method and compounds
|